Post-marketing drug withdrawals: pharmacovigilance success, regulatory problems : Arrêts de commercialisation de médicaments post-autorisation : succès de la pharmacovigilance, problèmes réglementaires
Modern pharmacovigilance began in the 1960s, since when the subject has grown markedly, interest having particularly increased since 2010. One index of its success is the increasing speed with which serious adverse drug reactions are discovered after marketing of a medicinal product. However, the sp...
| Main Author: | |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
Elsevier
2017
|
| _version_ | 1797087030749954048 |
|---|---|
| author | Aronson, J |
| author_facet | Aronson, J |
| author_sort | Aronson, J |
| collection | OXFORD |
| description | Modern pharmacovigilance began in the 1960s, since when the subject has grown markedly, interest having particularly increased since 2010. One index of its success is the increasing speed with which serious adverse drug reactions are discovered after marketing of a medicinal product. However, the speed with which products have subsequently been withdrawn as a result of the discovery of serious adverse reactions has not consistently changed. This highlights problems that regulators and manufacturers face when serious reactions are discovered, with difficulties in deciding which of several consequent actions to take: to add specific warnings (cautions) or contraindications to the product label; to issue a Direct Healthcare Professional Communication; to allow informed patients to decide whether they will take the drug; or, in the most serious cases, to withdraw the product or revoke the licence. Conflicts of interest may inhibit decision-making. Recommendations that arise from these observations are that: health professionals and patients should be more vigorously encouraged to report suspected adverse drug reactions; regulatory authorities and drug manufacturers should take quicker confirmatory action when serious suspected adverse drug reactions are reported, even anecdotally, with formal studies to test for causality conducted sooner rather than later, applying lower than usual thresholds for suspicion; temporary suspensions or restrictions could be considered during such assessments; universal guidelines are needed for determining when a drug should be withdrawn if serious adverse drug reactions are suspected; there should be more rigorous monitoring and verification of deaths and reporting of reasons for drop-outs during clinical trials, with more transparency in reporting adverse events and ready access to premarketing clinical study reports; post-marketing drug monitoring systems and medicines regulation in low-to-middle income economies, especially in Africa, where withdrawals are fewer than elsewhere, should be strengthened. |
| first_indexed | 2024-03-07T02:30:21Z |
| format | Journal article |
| id | oxford-uuid:a7075927-48dc-48f0-b32a-66c1f3182ae0 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T02:30:21Z |
| publishDate | 2017 |
| publisher | Elsevier |
| record_format | dspace |
| spelling | oxford-uuid:a7075927-48dc-48f0-b32a-66c1f3182ae02022-03-27T02:51:38ZPost-marketing drug withdrawals: pharmacovigilance success, regulatory problems : Arrêts de commercialisation de médicaments post-autorisation : succès de la pharmacovigilance, problèmes réglementairesJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:a7075927-48dc-48f0-b32a-66c1f3182ae0EnglishSymplectic Elements at OxfordElsevier2017Aronson, JModern pharmacovigilance began in the 1960s, since when the subject has grown markedly, interest having particularly increased since 2010. One index of its success is the increasing speed with which serious adverse drug reactions are discovered after marketing of a medicinal product. However, the speed with which products have subsequently been withdrawn as a result of the discovery of serious adverse reactions has not consistently changed. This highlights problems that regulators and manufacturers face when serious reactions are discovered, with difficulties in deciding which of several consequent actions to take: to add specific warnings (cautions) or contraindications to the product label; to issue a Direct Healthcare Professional Communication; to allow informed patients to decide whether they will take the drug; or, in the most serious cases, to withdraw the product or revoke the licence. Conflicts of interest may inhibit decision-making. Recommendations that arise from these observations are that: health professionals and patients should be more vigorously encouraged to report suspected adverse drug reactions; regulatory authorities and drug manufacturers should take quicker confirmatory action when serious suspected adverse drug reactions are reported, even anecdotally, with formal studies to test for causality conducted sooner rather than later, applying lower than usual thresholds for suspicion; temporary suspensions or restrictions could be considered during such assessments; universal guidelines are needed for determining when a drug should be withdrawn if serious adverse drug reactions are suspected; there should be more rigorous monitoring and verification of deaths and reporting of reasons for drop-outs during clinical trials, with more transparency in reporting adverse events and ready access to premarketing clinical study reports; post-marketing drug monitoring systems and medicines regulation in low-to-middle income economies, especially in Africa, where withdrawals are fewer than elsewhere, should be strengthened. |
| spellingShingle | Aronson, J Post-marketing drug withdrawals: pharmacovigilance success, regulatory problems : Arrêts de commercialisation de médicaments post-autorisation : succès de la pharmacovigilance, problèmes réglementaires |
| title | Post-marketing drug withdrawals: pharmacovigilance success, regulatory problems : Arrêts de commercialisation de médicaments post-autorisation : succès de la pharmacovigilance, problèmes réglementaires |
| title_full | Post-marketing drug withdrawals: pharmacovigilance success, regulatory problems : Arrêts de commercialisation de médicaments post-autorisation : succès de la pharmacovigilance, problèmes réglementaires |
| title_fullStr | Post-marketing drug withdrawals: pharmacovigilance success, regulatory problems : Arrêts de commercialisation de médicaments post-autorisation : succès de la pharmacovigilance, problèmes réglementaires |
| title_full_unstemmed | Post-marketing drug withdrawals: pharmacovigilance success, regulatory problems : Arrêts de commercialisation de médicaments post-autorisation : succès de la pharmacovigilance, problèmes réglementaires |
| title_short | Post-marketing drug withdrawals: pharmacovigilance success, regulatory problems : Arrêts de commercialisation de médicaments post-autorisation : succès de la pharmacovigilance, problèmes réglementaires |
| title_sort | post marketing drug withdrawals pharmacovigilance success regulatory problems arrets de commercialisation de medicaments post autorisation succes de la pharmacovigilance problemes reglementaires |
| work_keys_str_mv | AT aronsonj postmarketingdrugwithdrawalspharmacovigilancesuccessregulatoryproblemsarretsdecommercialisationdemedicamentspostautorisationsuccesdelapharmacovigilanceproblemesreglementaires |